Long-term ACE Inhibitor Use Linked to Increased Risk of Angioedema

Strategic Insights -

Researchers from the Albert Einstein Medical Center in Philadelphia reviewed the charts of 70 patients with angioedema (AE), a condition characterized by lip and tongue swelling, and found that long-term use of angiotensin-converting enzyme (ACE) inhibitors may cause AE in some patients. The study, published in the August 2004 issue of Chest, revealed that 64% of AE cases were attributed to ACE inhibitor use, with 11 patients (24%) developing AE after long-term treatment (6 months to 5 years) with these medications. The researchers noted that patients with a history of AE were more likely to experience severe reactions, including shortness of breath, respiratory failure, cough, and dysphagia.

Key Takeaways:

  • Long-term use of ACE inhibitors may increase the risk of angioedema (AE) in some patients, with 64% of AE cases attributed to ACE inhibitor use.
  • 11 patients (24%) developed AE after long-term treatment (6 months to 5 years) with ACE inhibitors, indicating a potential link between prolonged exposure and increased risk.
  • Patients with a history of AE were more likely to experience severe reactions, such as shortness of breath, respiratory failure, cough, and dysphagia.
  • ACE inhibitor use was the primary cause of AE in this study, highlighting the importance of monitoring patients for AE symptoms when on these medications.
  • Researchers recommend that healthcare providers avoid prescribing ACE inhibitors in patients with a history of AE.
  • The study's findings suggest that AE may become more common due to the increasing use of ACE inhibitors.
  • Lip and tongue swelling were present in all patients who experienced AE, emphasizing the severity of the condition.

Statistics:

  • 70 patients with angioedema were reviewed in the study, with 45 cases (64%) attributing AE to ACE inhibitor use.
  • 24% of patients developed AE after long-term treatment (6 months to 5 years) with ACE inhibitors.
  • 47% of patients presented with AE within 2 months of initial treatment.
  • 22% of patients had a history of AE.
  • 11 patients (24%) experienced severe reactions, including shortness of breath, respiratory failure, cough, and dysphagia.

Sources:

  • Chest, August 2004 issue
  • NewsRx.com & NewsRx.net, Health & Medicine Week editors, August 30, 2004